Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
SciSparc Ltd. ( (SPRC) ) has issued an announcement.
On February 18, 2025, SciSparc Ltd. announced a favorable settlement in a lawsuit filed in 2022 against six former directors, which alleged breaches of fiduciary duties related to a prior acquisition. The settlement includes a $411,000 cash payment to SciSparc and confirms its retention of exclusive global rights to its intellectual property, allowing SciSparc to focus on its core development programs. The agreement also results in the termination of a disputed licensing agreement with Dekel Pharmaceuticals Ltd., ensuring SciSparc’s continued focus on its core technologies without any further claims, commitments, or royalty obligations related to the agreement.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid-based therapies targeting central nervous system disorders. The company is engaged in developing treatments such as SCI-110 for Tourette Syndrome and Alzheimer’s disease agitation, as well as SCI-210 for autism and status epilepticus. Additionally, it holds a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.
YTD Price Performance: 27.04%
Average Trading Volume: 8,848,611
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.17M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.
